New targeted drug tested for Tough-to-Treat lung cancer
NCT ID NCT04940325
Summary
This study is testing an experimental drug called DS-1062a for people with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. About 100 participants will receive the drug by IV every three weeks to see if it shrinks their tumors and is safe. Researchers will also collect tissue and blood samples to learn which patients are most likely to benefit from this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François Baclesse
Caen, 14076, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94010, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Tenon
Paris, 75970, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut de Cancérologie, CHRU Morvan de Brest
Brest, 29200, France
Conditions
Explore the condition pages connected to this study.